Dog-allergy immunotherapy with Alutard SQ Dog in Swedish practice
Official title: Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
Run by Karolinska Institutet · NCT07651891 · Data updated 2026-11-12
This study tests whether Alutard SQ Dog immunotherapy helps adults with moderate-to-severe dog allergy when used in real-world Swedish care.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Karolinska Institutet Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 2 sites (Lund, Skåne County and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | October 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT07651891 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-50 with moderate-to-severe dog allergy confirmed by positive specific IgE, and deemed suitable for Alutard SQ Dog therapy.
✕Probably not a fit
Individuals with conditions that exclude immunotherapy or with non-allergic causes of symptoms may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, prospective before-and-after trial in Sweden where participants serve as their own controls. Baseline symptoms, lung function, nasal airflow, blood IgE levels, and symptom scores are recorded before and after a 30-minute dog exposure. Participants then receive ongoing allergen immunotherapy with Alutard SQ Dog for one year, with follow-up assessments including lung function, nasal airflow, IgE to Can f components, and symptom scores. The study aims to determine changes in objective and subjective measures of dog allergy after treatment in adults aged 18-50.
Why it matters
Potential benefit: If successful, participants may experience reduced allergy symptoms and improved lung and nasal function during dog exposure.
How similar studies have gone: Immunotherapy approaches for pet allergies have shown variable but often beneficial results in similar settings, though this exact dog-allergen immunotherapy in a before-and-after design is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria The subject has provided written informed consent to participate in the study. * Age 18-50 years. * Moderate-to-severe allergic symptoms upon exposure to dogs. * Dog allergy confirmed by positive specific IgE. * Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC). * Female subjects of childbearing potential must use adequate contraception. * A negative pregnancy test must be obtained prior to enrolment. Exclusion Criteria * Pregnancy or breastfeeding. * Autoimmune or connective tissue disease. * Cardiovascular disease. * Hepatic disease. * Renal disease. * Malignancy. * Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis). * Chronic obstructive or restrictive lung disease. * Treatment with medications that may interfere with the immune response. * Previous immunotherapy or chemotherapy. * Significant chronic disease. * Major metabolic disease. * Alcohol or substance abuse. * Mental or cognitive incapacity that may impair compliance with study procedures. * Known or suspected hypersensitivity to the study product. * Suspected or confirmed bacterial infection. * Clinically relevant allergy to house dust mite. * Current dog ownership. * Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate. * Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.
Where it's running
-
Lund University Hospital
Lund, Skåne County, Sweden Recruiting -
Trelleborg Hospital
Trelleborg, Skåne County, Sweden Recruiting
Study contacts
- Principal investigator: Lars Olaf Cardell — Karolinska Institutet, Division of ENT
- Study coordinator: Carl Skröder, MD
- Email: carl.skroder@ki.com
- Phone: +46 41055181
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
IOS-based platform to screen, diagnose, and manage COPD and asthma
This study tests an Impulse Oscillometry system to screen for and diagnose COPD and asthma and to help predict flare-ups over about a year, involving adults in China.
-
Mannan-Conjugated Allergoids for House Dust M mite Allergy
A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.
-
Mannan-conjugated Allergoids for House Dust Mite Allergy
A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.
-
REACH: Resources and Education to Help Kids with Asthma in School
A service model called REACH will try to improve school-based asthma care by coordinating care between healthcare, school, and home for children with asthma.
-
Beclometasone Dipropionate and Formoterol inhalation combo vs FOSTER in adults with asthma
This Phase 3 trial tests whether a beclometasone formoterol inhalation combo works as well or better than FOSTER for adults with asthma.
-
Test of SKB575 in adults with asthma
This study tests whether SKB575 helps people with asthma compared to a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.